| 119 | 6 | 89 |
| 下载次数 | 被引频次 | 阅读次数 |
目的:系统评价免疫吸附治疗扩张型心肌病(DCM)的疗效。方法:计算机检索中国期刊全文数据库(CNKI)、万方数据库、维普数据库(VIP)、Pubmed、Medline、EMbase、Cochrane Library数据库,根据纳入标准和排除标准筛选免疫吸附治疗DCM疗效的随机对照试验,检索日期为建库至2019年7月,提取相关数据,采用RevMan 5.3软件进行Meta分析。结果:本研究共纳入8篇英文文献,共计294例患者,其中试验组153例,对照组141例。Meta分析结果显示:试验组DCM患者左室射血分数(LVEF)高于对照组(MD=1.32,95%CI:0.18～2.46,P=0.02),左室舒张末内径(LVDD)低于对照组(MD=-2.77,95%CI:-4.59～-0.94,P=0.003)。结论:免疫吸附疗法对DCM患者具有较好的治疗效果。
Abstract：Objective:To systematically evaluate the efficacy of immunoadsorption therapy for dilated cardiomyopathy(DCM).Methods:The database were retrieved from building up to July 2019,including CNKI database,WangFang database,VIP database,Pubmed,Medline,EMbase and Cochrane Library.Randomized controlled trials about the efficacy of immunoadsorption therapy for DCM were screened according to the inclusion criteria and exclusion criteria.The effective data was extracted and analyzed by RevMan 5.3 software for meta-analysis.Results:A total of 8 studies involving 294 patients were included,with 153 cases in the experimental group and 141 cases in the control group.Meta-analysis results showed that the left ventricular ejection fraction(LVEF)of DCM patients in the experimental group was higher(MD=1.32,95%CI:0.18 to 2.46,P=0.02)and the left ventricular end-diastolic diameter(LVDD)was less(MD=-2.77,95% CI:-4.59 to-0.94,P=0.003)than that in the control group.Conclusion:Immunoadsorption therapy is effective for DCM patients.
[1] Ameling S,Bhardwaj G,Hammer E,et al.Changes of myocardial gene expression and protein composition in patients with dilated cardiomyopathy after immunoadsorption with subsequent immunoglobulin substitution[J].Basic Res Cardiol,2017,112(4):40.
[2] Ponikowski P,Voors A A,Anker,S D,et al.2016ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure:The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology(ESC)Developed with the special contribution of the Heart Failure Association(HFA)of the ESC[J].Eur heart Fail,2016,18(8):891-975.
[3] Felix S B,Beug D,Dorr M.Immunoadsorption therapy in dilated cardiomyopathy[J].Expert Rev Cardiovasc Ther,2015,13(2):145-152.
[4] Kaya Z,Katus H A,Rose N R.Cardiac troponins and autoimmunity:their role in the pathogenesis of myocarditis and of heart failure[J].Clin Immunol,2010,134(1):80-88.
[5] Ameling S,Herda L R,Hammer E,et al.Myocardial gene expression profiles and cardiodepressant autoantibodies predict response of patients with dilated cardiomyopathy to immunoadsorption therapy[J].Eur Heart J,2013,34(9):666-675.
[6] Yancy C W,Jessup M,Bozkurt B,et al.2017 ACC/AHA/HFSA focused update of the 2013 ACCF/AHA guideline for the management of heart failure:a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America[J].Circulation,2017,136(6):e137-e161.
[7] Caforio A L,Mahon N J,McKenna W J.Cardiac autoantibodies to myosin and other heart-specific autoantigens in myocarditis and dilated cardiomyopathy[J].Autoimmunity,2001,34(3):199-204.
[8] Felix S B,Staudt A,Dorffel W V,et al.Hemodynamic effects of immunoadsorption and subsequent immunoglobulin substitution in dilated cardiomyopathy:threemonth results from a randomized study[J].J Am Coll Cardiol,2000,35(6):1590-1598.
[9] Staudt A,Chaper F,Stangl V,et al.Immunohistological changes in dilated cardiomyopathy induced by immunoadsorption therapy and subsequent immunoglobulin substitution[J].Circulation,2001,103(22):2681-2686.
[10]Knebel F,Bohm M,Staudt A,et al.Reduction of morbidity by immunoadsorption therapy in patients with dilated cardiomyopathy[J].Int J Cardiol,2004,97(3):517-520.
[11]Staudt A,Staudt Y,Hummel A,et al.Effects of immunoadsorption on the Nt-BNP and Nt-ANP plasma levels of patients suffering from dilated cardiomyopathy[J].Ther Apher Dial,2006,10(1):42-48.
[12]Herda L R,Trimpert C,Nauke U,et al.Effects of immunoadsorption and subsequent immunoglobulin G substitution on cardiopulmonary exercise capacity in patients with dilated cardiomyopathy[J].Am Heart J,2010,159(5):809-816.
[13]Bulut D,reutzenberg G,Mugge A.The number of regulatory T cells correlates with hemodynamic improvement in patients with inflammatory dilated cardiomyopathy after immunoadsorption therapy[J].Scand J Immunol,2013,77(1):54-61.
[14]Müller J,Wallukat G,Dandel M,et al.Immunoglobulin adsorption in patients with idiopathic dilated cardiomyopathy[J].Circulation 2000,101(4):385-391.
[15] Weinmann K,Werner J,Koenig W,et al.Add-on immunoadsorption shortly-after optimal medical treatment further significantly and persistently improves cardiac function and symptoms in recent-onset heart failurea single center experience[J].Biomolecules,2018,8(4):E133.
[16]刘文玲，李忠佑，刘欣．解读2016年ESC关于扩张型心肌病和收缩功能减低性非扩张型心肌病定义的修正[J]．中国循环杂志，2016,31(6):532-535.
[17]Pezawas T,Diedrich A,Winker R,et al.Multiple autonomic and repolarization investigation of sudden cardiac death in dilated cardiomyopathy and controls[J].Circ Arrhythm Electrophysiol,2014,7(6):1101-1108.
基本信息:
中图分类号:R542.2
引用信息:
[1]鲍荣辉,周畅,周军,等.免疫吸附治疗扩张型心肌病疗效的Meta分析[J].巴楚医学,2019,2(04):48-53.
2019-10-07
2019
2019-12-13
2019
2019-11-18
1
2019-12-30
2019-12-30